VINC Vincerx Inc

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

SVB Securities Global Biopharma Conference Presentation Details

Date: Thursday, February 16, 2023

Time: 1:40 p.m. ET

Webcast:

An archived webcast will be accessible in the section of the Company’s website for approximately 90 days following the event.

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Vincerx) is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. The company’s diverse pipeline consists of enitociclib, currently in Phase 1, and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236, in Phase 1, and preclinical next-generation antibody drug conjugates, VIP943 and VIP924.

Vincerx Pharma is based in Palo Alto, Calif., and has a research facility in Monheim, Germany. For more information, please visit .

Contacts

Bruce Mackle

LifeSci Advisors, LLC

646-889-1200



EN
06/02/2023

Underlying

VINCVincerx Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vincerx Inc

 PRESS RELEASE
Free
VINC VINCERX INC

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeti...

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the re-convened Special Meeting of Stockholders to...

July 16, 2025 1 EN
 PRESS RELEASE
Free
VINC VINCERX INC

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissol...

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced updated information regarding the Special Meeting of ...

July 7, 2025 1 EN
 PRESS RELEASE
Free
VINC VINCERX INC

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will R...

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the “Dissolution Proposal”), which was originally scheduled for earlier today, has been adjourned u...

June 18, 2025 1 EN
 PRESS RELEASE
Free
VINC VINCERX INC

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregi...

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (“SEC”) on or about April 28, 2025, which will remove Vincerx’s common stock from listing a...

April 17, 2025 1 EN
 PRESS RELEASE
Free
VINC VINCERX INC

Vincerx Pharma Announces Termination of Letter of Intent and Board Aut...

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company’s board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. “I want to expres...

April 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch